Myeloma
Conditions
Interventions
Gold Standard:satisfying either 1 or2:
1 Monoclonal M protein was found in serum and/or urine, and the proportion of monoclonal plasma cells in bone marrow was more than 10%, or plasma cel
2 If there is no 
(GE 
DMI 
PET/CT), 
PET/MR 
(Simens 
PET/MR) 
 
Sponsors
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 85 years, male and female, a total of 60 patients; 2.The patient is a newly diagnosed multiple myeloma patient (satisfying either 2.1 or 2.2): 2.1 Monoclonal M protein was found in serum and/or urine, and the proportion of monoclonal plasma cells in bone marrow was more than 10%, or plasma cell tumors were proved by biopsy; 2.2 If there is no monoclonal M protein in serum and/or urine, the bone marrow monoclonal plasmacytes (>30%) or biopsy is required for plasmacytoma; 3. Good compliance; 4. Agree to participate in this clinical trial and sign the informed consent form; 5. No family planning within three months.
Exclusion criteria
Exclusion criteria: 1.Combination of other advanced malignant tumors of the blood or other systems within 5 years. 2.Contraindications of magnetic resonance examination: implantation of functional electronic devices and various stimulators such as cardiac pacemakers, cochlear implants, ferromagnetic materials (such as iron, cobalt, nickel, etc.). An implanted perfusion device, such as an insulin or other perfusion pump. 3.Diabetics or other people with poor blood glucose control (fasting blood glucose is over 10 mmol/L on the day of the trial). If the subjects cannot confirm their blood glucose status, the testing institute is responsible for providing blood glucose monitoring. 4.Patients who underwent organ transplantation or heart and kidney surgery in recent 3 months. 5.Claustrophobic. 6.Pregnant and potential pregnant women,lactating women. 7.Those with severe mental symptoms or who are not conscious enough to cooperate with the examiner.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;SUVmax; | — |
Countries
China
Contacts
Public ContactBiao Li, Jianqing Mi
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Outcome results
None listed